Why the study?
Does pentamidine isethionate effectively treat pentavalent antimonial-resistant kala-azar and what are its safety limitations?
Does pentamidine isethionate effectively treat pentavalent antimonial-resistant kala-azar and what are its safety limitations?
Pentamidine isethionate is effective for resistant kala-azar but requires close clinical, electrocardiographic, and biochemical monitoring due to cardiotoxicity and metabolic disturbances.
Answers are grounded in this paper and cite their sources.
Supports monitored use for resistant kala-azar; leaves open need for safer regimens and RCTs.
Pentamidine isethionate was found to be a very effective therapeutic agent in the treatment of pentavalent antimonial-resistant cases of kala-azar. Cardiotoxicity and metabolic disturbance (diabetes mellitus-like state) were found to be limiting factors in the use of this drug. Frequent clinical, electrocardiographic and biochemical observations are required during and after course of treatment and pentamidine treatment should be restricted to in-patients in hospitals.
No takes yet. Share an insight, caveat, or question.
T. K. Jha (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: